The High Commissioner was provided with a tour of the vaccine fill-finish facility which is currently contracted by the UK Government to manufacture the Oxford/AstraZeneca COVID-19 vaccine until August 2022
The High Commissioner of India, Gaitri Issar Kumar, visited Wockhardt UK recently at its sterile pharmaceutical manufacturing facility in Wrexham, North Wales. The visit was part of a tour of India-backed or supported businesses in the United Kingdom, Wockhardt said in a statement.
It also said that as part of her visit, The High Commissioner was provided with a tour of the vaccine fill-finish facility which is currently contracted by the UK Government to manufacture the Oxford/AstraZeneca COVID-19 vaccine until August 2022. She was joined by the Indian Honorary Consul for Wales, Raj Aggarwal OBE, RNR.
During the visit, Kumar said, “The United Kingdom’s vaccination programme has been a beacon for the world in many ways. It is a matter of great satisfaction that an India-UK collaboration in vaccine manufacturing here in the UK has played a vital part in the roll out. The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector.”
Adding to it, Dr Habil Khorakiwala, Founder Chairman, Wockhardt, also said, “The COVID-19 pandemic has been a challenge for all and it needed a concerted effort to overcome that challenge. We are proud to be an India-led company working in collaboration with the UK government with our international operations in Wales. It is an honour to be recognised for our capability and commitment by the visit from the Indian High Commissioner to the UK.”
